Table 9.
Name of Drug | Amyloid β Residues Targeted |
---|---|
aducanumab | 3–7 (6, 25) |
gantenerumab | 3–11 and 18–27 (6, 25) |
crenezumab | 13–24 (6, 25) |
solanezumab | 16–26 (6, 25) |
lecanemab | 1–16 (6, 25) |
donanemab | 3–7 (25) |
These drugs are in a stage of clinical trials and the residues they target are also shown with them. This was used for the analysis of the residues as it indicates what other researchers predicted significant residues are.